CU23218A3 - Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7 - Google Patents
Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7Info
- Publication number
- CU23218A3 CU23218A3 CU20030188A CU20030188A CU23218A3 CU 23218 A3 CU23218 A3 CU 23218A3 CU 20030188 A CU20030188 A CU 20030188A CU 20030188 A CU20030188 A CU 20030188A CU 23218 A3 CU23218 A3 CU 23218A3
- Authority
- CU
- Cuba
- Prior art keywords
- spirociclic
- derivatives
- new
- phosphodiesterase inhibitors
- inhibitors
- Prior art date
Links
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 abstract 2
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invencion provee compuestos que son inhibidores de PDE7, que tienen las siguientes formulas (I), (II) y (III) ESPACIO PARA FORMULA. En donde X1, X2, X3, X4, X, Y, Z, A y Z1 son lo definido en la memoria descriptiva, mÉtodos para prepararlos y su uso para el tratamiento de trastornos para los cuales la terapia con un inhibidor de PDE7 es relevante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2001/003355 WO2002076953A1 (en) | 2001-03-21 | 2001-03-21 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23218A3 true CU23218A3 (es) | 2007-07-20 |
Family
ID=8164349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20030188A CU23218A3 (es) | 2001-03-21 | 2003-08-29 | Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7 |
Country Status (46)
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| GB0230195D0 (en) * | 2002-12-24 | 2003-02-05 | Biofocus Plc | Compound Libraries |
| GEP20084393B (en) | 2003-04-24 | 2008-06-10 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| WO2005013997A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
| JP4810426B2 (ja) | 2004-07-01 | 2011-11-09 | 第一三共株式会社 | Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体 |
| RU2007132865A (ru) * | 2005-03-01 | 2009-03-10 | Пфайзер Лимитед (GB) | Применение ингибиторов pde7 для лечения невропатической боли |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| GB0504209D0 (en) * | 2005-03-01 | 2005-04-06 | Pfizer Ltd | New use of PDE7 inhibitors |
| KR100680497B1 (ko) * | 2005-07-25 | 2007-02-08 | 엘지전자 주식회사 | 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법 |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP2009514969A (ja) | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
| BRPI0619126A2 (pt) | 2005-12-02 | 2011-09-13 | Pfizer Ltd | derivados espirocìclicos, composição farmacêutica e usos dos mesmos |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| AU2008230710B2 (en) * | 2007-03-27 | 2014-04-10 | Omeros Corporation | The use of PDE7 inhibitors for the treatment of movement disorders |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US20100216823A1 (en) * | 2007-05-24 | 2010-08-26 | Pfizer Inc. | Spirocyclic Derivatives |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR20220047894A (ko) | 2010-11-08 | 2022-04-19 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| CN108602815B (zh) * | 2015-12-16 | 2020-07-28 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107382976A (zh) * | 2017-07-04 | 2017-11-24 | 孙秀芹 | 一种治疗盆腔炎的化合物及制备方法和应用 |
| EP3652180B1 (en) * | 2017-07-12 | 2023-11-29 | Dart NeuroScience, LLC | Substituted benzoxazole and benzofuran compounds as pde7 inhibitors |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20250048344A (ko) | 2022-08-18 | 2025-04-08 | 미토디큐어 게엠베하 | 만성 피로, 탈진 및/또는 운동 불내성과 연관된 질환의 치료 및 예방을 위한 포스포디에스테라제-7 억제 활성을 갖는 치료제의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815979A (ja) | 1981-07-11 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体およびその製造法 |
| US4764512A (en) | 1986-08-27 | 1988-08-16 | Rorer Pharmaceutical Corporation | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| US5536716A (en) * | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| RO115804B1 (ro) | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| US5602143A (en) * | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| CZ119398A3 (cs) * | 1995-10-17 | 1998-09-16 | Astra Aktiebolag | Farmaceuticky účinné sloučeniny na bázi chinazolinu |
| CN1205008A (zh) * | 1996-08-30 | 1999-01-13 | 协和发酵工业株式会社 | 咪唑并喹唑啉衍生物 |
| WO2000066560A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| SI1173210T1 (en) | 1999-05-04 | 2005-02-28 | Wyeth | Contraceptive compositions containing antiprogestinic and progestinic |
| WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2001
- 2001-03-21 AP APAP/P/2003/002857A patent/AP1699A/en active
- 2001-03-21 WO PCT/EP2001/003355 patent/WO2002076953A1/en not_active Ceased
-
2002
- 2002-03-05 TW TW091104028A patent/TWI267509B/zh not_active IP Right Cessation
- 2002-03-18 EP EP02732544A patent/EP1373224B1/en not_active Expired - Lifetime
- 2002-03-18 SI SI200230587T patent/SI1373224T1/sl unknown
- 2002-03-18 RS YUP-740/03A patent/RS50429B/sr unknown
- 2002-03-18 KR KR1020037012247A patent/KR100617435B1/ko not_active Expired - Fee Related
- 2002-03-18 HR HR20030740A patent/HRP20030740A2/hr not_active Application Discontinuation
- 2002-03-18 CA CA002441313A patent/CA2441313C/en not_active Expired - Fee Related
- 2002-03-18 CZ CZ20032451A patent/CZ20032451A3/cs unknown
- 2002-03-18 AU AU2002304800A patent/AU2002304800B2/en not_active Ceased
- 2002-03-18 TN TNPCT/EP2002/003594A patent/TNSN03076A1/en unknown
- 2002-03-18 MY MYPI20020954A patent/MY142045A/en unknown
- 2002-03-18 ES ES02732544T patent/ES2288552T3/es not_active Expired - Lifetime
- 2002-03-18 UA UA2003098601A patent/UA74243C2/uk unknown
- 2002-03-18 SK SK1156-2003A patent/SK11562003A3/sk not_active Application Discontinuation
- 2002-03-18 NZ NZ527847A patent/NZ527847A/en unknown
- 2002-03-18 DE DE60221233T patent/DE60221233T2/de not_active Expired - Lifetime
- 2002-03-18 MX MXPA03008485A patent/MXPA03008485A/es active IP Right Grant
- 2002-03-18 EE EEP200300459A patent/EE200300459A/xx unknown
- 2002-03-18 JP JP2002573763A patent/JP4086663B2/ja not_active Expired - Fee Related
- 2002-03-18 CN CNB028069714A patent/CN100447136C/zh not_active Expired - Fee Related
- 2002-03-18 HU HU0303637A patent/HUP0303637A3/hu unknown
- 2002-03-18 DK DK02732544T patent/DK1373224T3/da active
- 2002-03-18 EP EP07104642A patent/EP1801106A3/en not_active Withdrawn
- 2002-03-18 GE GE5294A patent/GEP20053631B/en unknown
- 2002-03-18 BR BR0208192-0A patent/BR0208192A/pt not_active IP Right Cessation
- 2002-03-18 WO PCT/EP2002/003594 patent/WO2002074754A1/en not_active Ceased
- 2002-03-18 PL PL02367058A patent/PL367058A1/xx not_active Application Discontinuation
- 2002-03-18 EA EA200300906A patent/EA006815B1/ru unknown
- 2002-03-18 IL IL15765902A patent/IL157659A0/xx active IP Right Grant
- 2002-03-18 OA OA1200300226A patent/OA12454A/en unknown
- 2002-03-18 PT PT02732544T patent/PT1373224E/pt unknown
- 2002-03-18 AT AT02732544T patent/ATE367381T1/de not_active IP Right Cessation
- 2002-03-19 US US10/101,996 patent/US20020198198A1/en not_active Abandoned
- 2002-03-20 AR ARP020100993A patent/AR033617A1/es active IP Right Grant
- 2002-03-20 PE PE2002000212A patent/PE20021010A1/es not_active Application Discontinuation
- 2002-03-20 GT GT200200053A patent/GT200200053A/es unknown
- 2002-03-20 PA PA20028541601A patent/PA8541601A1/es unknown
- 2002-03-20 SV SV2002000925A patent/SV2003000925A/es not_active Application Discontinuation
-
2003
- 2003-08-25 ZA ZA200306601A patent/ZA200306601B/en unknown
- 2003-08-27 EC EC2003004750A patent/ECSP034750A/es unknown
- 2003-08-28 IL IL157659A patent/IL157659A/en not_active IP Right Cessation
- 2003-08-29 IS IS6934A patent/IS2529B/is unknown
- 2003-08-29 CU CU20030188A patent/CU23218A3/es not_active IP Right Cessation
- 2003-09-12 MA MA27310A patent/MA27001A1/fr unknown
- 2003-09-17 BG BG108181A patent/BG108181A/xx unknown
- 2003-09-19 NO NO20034187A patent/NO326086B1/no not_active IP Right Cessation
-
2004
- 2004-05-24 US US10/852,404 patent/US7214676B2/en not_active Expired - Fee Related
-
2006
- 2006-10-20 US US11/551,687 patent/US20070049558A1/en not_active Abandoned
-
2007
- 2007-08-30 CY CY20071101121T patent/CY1106829T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23218A3 (es) | Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa - 7 | |
| CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
| CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| ECSP045476A (es) | Tiazolidinonas, su preparación y su uso como medicamentos | |
| SV2004001459A (es) | 2- (piridin-2-ilamino) -pirido [2,3-d]pirimidin-7-onas ref. pc20501 | |
| UY28572A1 (es) | Compuestos novedosos | |
| PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
| PA8693101A1 (es) | Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| ECSP034774A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ECSP066643A (es) | PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 | |
| HN2001000019A (es) | Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4. | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| UY28342A1 (es) | Nuevos compuestos | |
| BRPI0412404A (pt) | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea | |
| UY30327A1 (es) | Nuevos compuestos ii | |
| UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
| UY29253A1 (es) | 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento | |
| ECSP066717A (es) | Compuestos de quinolina sustituidos | |
| SV2003001173A (es) | 1-alquil o 1-cicloalquil-triazolo [4,3-a] quinazolin-5- onas como inhibidoras de fosfodiesterasa | |
| CR9663A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| PA8555501A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse (for not paying fees) |